Blue Water Ventures Int'l Inc (BWVI)

[DFLY]

Some news out...Psycheceutical’s Chief Visionary Officer Zappy Zapolin Speaking at Legacy Investment Summit Alongside Entrepreneur Peter Diamandis.
Zapolin Set to Outline the Lucrative Financial Potential of Psychedelic Medicine


MIAMI, FL — March 28, 2022 — Psycheceutical, Inc., a wholly owned subsidiary of
Psycheceutical Bioscience, Inc. (OTC: BWVI), a bioscience company dedicated to the
development and commercialization of psychedelic medicines, has announced that
Chief Visionary Officer Zappy Zapolin will be a featured presenter at the esteemed
Legacy Investment Summit 2022, to be held at the Mandarin Oriental Hotel in
Washington, D.C. on March 31 and April 1.
Zapolin’s session, entitled “Psychedelics: The Medicine of the Future,” aims to educate
attendees about the very real potential of funding their retirement by being early
investors in this emerging sector. Experts predict that psychedelic medicine will provide
a major breakthrough in the area of mental health and addiction treatment, with an
estimated global market size in the hundreds of billions.
As an investor, advisor, and filmmaker, Zappy Zapolin is one of the foremost experts in
psychedelic medicinal therapies and companies. In the early days of the internet,
Zapolin purchased and sold multiple domain names for up to 8,650% returns. This
ability to identify massive trends has put Zappy ahead of the mainstream investing
curve for decades. Since then, he’s made two documentaries on the healing power of
psychedelics and invested in early-stage medical psychedelic companies for gains up to
1,000%.
Keynoting the conference is renowned entrepreneur and investor Peter Diamandis.
Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Diamandis
has started over 20 companies in the areas of longevity, space, venture capital, and
education. He is the founder and executive chairman of the XPRIZE Foundation, the
executive founder of Singularity University, co-founder of BOLD Capital Partners, and
co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company.
“It is truly an honor to be part of one of the premier investment conferences in the
world,” commented Zapolin. “My passion is bringing people into the world of psychedelic
medicine, both through financial investment as well as personal experiences. Investing
in psychedelic companies today is like buying pharmaceutical stocks in the 1920s or
biotech stocks in the 1990s. Given the promise of these new therapies to treat the
global mental health crisis, the upside is enormous.”
To learn more about the conference and to buy tickets, please visit
https://www.legacyinvestmentsummit.com


About Psycheceutical, Inc.
Psycheceutical, Inc. is the wholly owned subsidiary of Psycheceutical Bioscience, Inc.
(OTC: BWVI). Psycheceutical is developing cutting-edge delivery technologies to
support safe and effective psychedelic pharmaceutical medicines. Powered by a team
with more than 100 years' combined experience in development, regulatory approval
processes, and commercialization across the pharmaceutical industry, Psycheceutical
is on a mission to bring safety and efficacy to psychedelic compounds. Learn more at
https://psycheceutical.com/


Forward-Looking Statements:
Certain statements in this news release related to the Company constitute "forwardlooking information" within the meaning of applicable securities laws and are
prospective in nature. Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events and are therefore
subject to risks and uncertainties which could cause actual results to differ materially
from the future results expressed or implied by the forward-looking statements. These
uncertainties include, but are not limited to, (i) general market growth for and
acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and
market volatility, (iii) general economic conditions, (iv) governmental approvals and
compliance with regulations, (v) product research and development and clinical trial
risks, (vi) incorrect underlying assumptions, and (vii) our future business development,
results of operations, and financial condition. These statements generally can be
identified using forward-looking words such as "will," “may,” “should,” “could,” "intend,”
“estimate,” “plan,” "anticipate,” "expect,” “believe,” “potential” or “continue,” or the
negative thereof or similar variations. All information provided in this press release is as
of the date of this press release, and we undertake no duty to update such information,
except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications
[e-mail]